cyrilzakka/clinical-trials huggingface dataset:
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

CD56 is the archetypal phenotypic marker of natural killer cells but can actually be expressed by many more immune cells, including alpha, beta T cells, gamma, delta T cells, dendritic cells, and monocytes. Common to all these CD56 expressing cell types have strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical , functional deficiencies and phenotypic alterations of the CD56 immune cell fraction have been reported in patients with various infectious, autoimmune, or malignant diseases.CD56 is also known as neural cell adhesion molecule (NCAM).

Hematologic malignancies are a heterogeneous group of diseases of diverse incidence, prognosis and etiology that arise from malignant transformation of cells from the bone marrow or the lymphatic system.There are two major groups of Hematologic malignancies according to their cell lineage: Myeloid and lymphoid. Lymphoid neoplasms are a varied group that includes non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia and multiple myeloma (MM).myeloid neoplasms and acute leukaemia include: Myeloproliferative neoplasms (MPN), Myelodysplastic/myeloproliferative neoplasms (MDS/MPN), Myelodysplastic syndromes (MDS), Acute myeloid leukaemia (AML), Acute leukemias of ambiguous lineage, B-lymphoblastic leukaemia/lymphoma, T-lymphoblastic leukaemia/lymphoma.The exact causes of Hematologic malignancies are still unknown although multiple epidemiological studies have reported an association between the development of Hematologic malignancies and several risk factors. Some factors are well documented to increase the risk of some types of leukaemia such as benzene exposure and ionizing radiation.However, many other factors were observed to have an association with Hematologic malignancies such as age, gender, tobacco smoking , obesity , hepatitis C virus (HCV) infection , family history , and environmental exposure to pesticides but with no clear evidence.

CD56 was found to be ectopically expressed in multiple myeloma. A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Eligibility Criteria:
Inclusion Criteria:

* Patients with hematologic malignancies.
* Newly diagnosed

Exclusion Criteria:

* Patients with hematologic disorders other than hematologic malignancies.
Analyzing Orthopedic Patient Experience Patterns in Medical Trials

Clinical study enrollment has historically been heavily biased toward specific demographics.

Several people will be invited to participate in this study so that it may collect a variety of data about orthopedic clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.

People with orthopedic disorders who are invited to take part in medical research will benefit from the analysis of the data.


Eligibility Criteria:
Inclusion Criteria:

* Patient has been diagnosed with orthopedic disorder
* Patient has self-identified as planning to enroll in an interventional clinical trial
* Patient is 18 years old

Exclusion Criteria:

* ECOG score of 4
* Patient is pregnant
* Inability to perform regular electronic reporting
* Patient does not understand, sign, and return consent form
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy

* Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day)
* Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo

Eligibility Criteria:
Inclusion Criteria:

* Type 2 Diabetes nephropathy
* Urinary albumin excretion 1-3g/24hours
* Serum creatinine \< 3mg/dl

Exclusion Criteria:

* Type 1 diabetes mellitus
* Renal diseases other than type 2 Diabetes nephropathy
* Renal artery stenosis
* Severe heart diseases
* Tuberculosis
Ventilation Support for the PREvenTion of EXTubation Failure

Reintubation after failed extubation would be associated with increased mortality. Therefore, extubation failure remains a major concern in ICU. Few randomized controlled studies have assessed the benefit for a systematic respiratory support (noninvasive ventilation or high flow nasal cannula) applied at the time of extubation to reduce reintubation rates in patients at high and low risk for reintubation. In addition, these studies reported discordant results. Therefore, there are some concerns regarding effectiveness and systematic uptake of a respiratory support after extubation into usual practice.

The aim of this trial is to determine whether a protocolized postextubation respiratory support including High-flow Nasal Oxygen (HFNO) and Noninvasive Ventilation (NIV) could reduce the rate of reintubation in comparison with usual practice. Therefore, all consecutively eligible patients for the study, will be assigned to a protocol arm in accordance with the randomized period

Eligibility Criteria:
Inclusion Criteria:

* Adult patients
* Intubated more than 24 hours in the ICU
* Ready for a scheduled extubation then extubated

Exclusion Criteria:

* Contraindication to HFNO or NIV
* Underlying chronic neuromuscular disease
* Unplanned extubation (accidental or self-extubation)
* With a do-not-reintubate order at time of extubation
* Tracheotomia
Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit

The investigators will randomize smokers to receive 1) Varenicline + smoking cessation/reduction counseling or 2) Placebo pill + smoking cessation/reduction counseling. Neither the participants nor the research therapists/evaluators will know to which condition (active or placebo pill) the participants have been assigned i.e., a double-blind study). The medication and weekly counseling will occur for 28 days. Participants will complete assessment measures just before the start of treatment (baseline), at the end-of-treatment, at 1-month, 3-month, and at 6-months to determine if there are differences in tobacco use between treatment groups.


Eligibility Criteria:
Inclusion Criteria:

* Must smoke at least 10 cigarettes per day for past 6-months
* Must have a working cellular or land-line phone

Exclusion Criteria:

* Must not be thinking of quitting in the next 30 days, but be interested in cutting down- Must not regularly (more than 1x/month) use tobacco products other than cigarettes
* Must not be currently receiving tobacco dependence treatment counseling
* Must not currently be taking varenicline, bupropion, nortriptyline, or any nicotine preparations (gum, lozenge, patch, spray, inhaler)
* Must not have positive screen on SCID-I/NP Psychotic Screen
* Must have no contraindications to using varenicline, including pregnancy, as measured by Medical History Form
Seated Time for 90% Incidence of Hypotension

The study will determine the 90% effective seated time after intrathecal injection of hyperbaric bupivacaine to avoid hypotension in patients undergoing cesarean delivery.

The study will use a Biased Coin Design (BCD), up-and-down sequential method, to determine the ET90 for absence of hypotension during Cesarean delivery. In this methodology, the first patient will be assigned an a priori initial seated time. Any other patient will be assigned a seated time based on the presence or absence of hypotension in the previous patient. If the previous patient developed hypotension, then the new patient will be seated for a longer time, which will be equal to the seated time of the previous patient plus a pre-determined time increment (up to an also pre-determined maximum allowed time). If no hypotension occurred to the previous patient, the new patient will be assigned one seated time from two choices: The same seated time that has been assigned to the previous patient, or a seated time shorter than that of the previous patient by a pre-determined time decrement (the pre-determined time increment and decrement are the same). The choice will be determined from a biased coin result, with a probability of 0.9 for assigning 'the same as previous' seated time and a probability of 0.1 for assigning a 'shorter seated time'.

Eligibility Criteria:
Inclusion Criteria:

* Patients with singleton pregnancies scheduled for elective cesarean delivery

Exclusion Criteria:

* BMI\>35
* Unable to communicate in study language
* ASA greater than 2
* Hypertensive disease of pregnancy
Liposomal Bupivacaine vs Bupivacaine for Pain Control After Sternotomy

Researchers hope to learn whether giving the longer-acting local anesthetic liposomal bupivacaine prior to closing the sternum is more effective in managing pain following sternotomy, than in patients who received standard bupivacaine before sternal closure. Researchers will measure this based on how much IV pain medication is used, rates on confusion, and time to remove the breathing tube.


Eligibility Criteria:
Inclusion Criteria:

* Adults over the age of 18 who present for elective open heart surgery that requires a sternotomy.

Exclusion Criteria:

* Urgent and emergency procedures,
* preexisting sternal infections,
* prior sternotomy,
* preexisting pain syndromes,
* current chronic home opioid use,
* anterior rib or sternal masses,
* allergy to any of the components of liposomal bupivacaine and plain bupivacaine.
Decision-Making and the Relationship to Food Intake in Kids

The purpose of this 18-month project is to investigate how decision-making influences food choice and consumption in children ages 7 to 11 years old. Although several studies suggest that the ability to make good decisions relates to eating behaviors, no studies have looked at how food reward influences the decision-making process to impact actual food intake. This proposal will answer these questions and bridge this gap in knowledge, which could lead to the development of more effective interventions for childhood obesity. To accomplish this, the investigators have assembled a diverse team with expertise in food intake, nutrition, and decision sciences. First, the investigators will establish if there are differences in decision-making between children varying in weight status. Second, the investigators will determine if performance on behavioral decision-making tasks relates to food consumption in the laboratory. Third, the investigators will examine response functional magnetic resonance imaging (fMRI) blood-oxygen-level-dependent (BOLD) response to various rewards (i.e. food and money) and determine if this is influenced by child weight status. Fourth, the investigators will examine differences in fMRI BOLD at rest in decision-making regions are correlated with food intake and weight status. Eighty-two children will participate in our study. The long-term goal of this project is to investigate if there are differences in brain regions corresponding to these behaviors in overweight children and if these differences relate to eating behaviors in this population. Children will undergo fMRI while playing a reward task as well as consume meals in our laboratory. Decision-making will also be assessed by having children complete various behavioral measurements of reward and inhibitory control.


Eligibility Criteria:
Inclusion Criteria:

* Right-handed
* English as native language
* Reading at/above grade level
* Not Claustrophobic
* Generally Healthy

Exclusion Criteria:

* Left-handedness
* Metal in or on body that cannot be removed
* Claustrophobia
* Medication usage that may alter brain activity or blood flow
* Medical disorder that may impact comfort of safety in MRI scanner
* Food Allergies
* Dietary Restrictions
* Learning Disabilities
* Psychiatric Disorders
Efficacy of Non-invasive NESA Neuromodulation in Fibromyalgia

Fibromyalgia is a chronic condition that causes pain throughout the body, fatigue and other symptoms. Among the most common clinical symptoms are sleep and anxiety disorders. All these symptoms are very disabling and have a negative impact on the quality of life of these people.

There is currently no curative treatment for this pathology and current treatments focus their efforts on reducing the intensity of the symptoms. The current approach is mainly pharmacological, with the possible side effects that this entails.

The NESA XSIGNAL® device is a non-invasive, low-frequency neuromodulation device that uses microcurrents to restore the electrical balance in the body. This technology is approved as medical equipment and is CE marked (attached in separate files).

This non-invasive neuromodulation equipment is beginning to show promising results in patients with sleep disorders. So it can be a useful tool to reduce the impact on the quality of life of people with fibromyalgia.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years of age
* Diagnosis of Fibromyalgia meeting ACR 1990/20101,2 criteria, made by a physician, documented by a clinical report.
* Diagnosis of Fibromyalgia made at least 12 months ago
* Stable baseline treatment in the month prior to inclusion in the study
* Signed informed consent
* In normal condition and mentally competent to participate in the study.
* Able to complete the study questionnaires.

Exclusion Criteria:

* Have any of the following contraindications for treatment with NESA XSIGNAL®: pacemakers, internal bleeding, not applying electrodes to skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia of electricity.
* Failure to sign the informed consent form.
* Active chronic inflammatory joint diseases.
* Active neurological diseases with central or peripheral nervous system involvement.
* Active systemic autoimmune diseases
* Psychotic disorders
* Active concomitant neoplastic or infectious processes
* Medication changes in the month prior to study inclusion or throughout the duration of the study.
Comparative Effects of Heavy Slow Resistance Training and Eccentric Overload Training in Runners

Patellar Tendinopathy (PT) also known as Jumper's knee, is characterized by multifaceted activity-related pathology causing anterior knee pain and patellar-tendon dysfunction. It most commonly affects athletic activities that involve jumping and running. Tendinopathy is most likely to be related to mechanical loading and overuse. Athletes suffer from insidious well-localized pain, typically as the athlete starts the activity. Conservative treatment is the first line of treatment in tendinopathy, however, there is no consensus regarding the best treatment. In acute conditions, relative rest rather than immobilization is preferred. The most popular non-operative treatment involves eccentric exercise (EE). It is commonly accepted that surgical treatment must be indicated in motivated patients if carefully followed conservative treatment (physical training, injections, ESWT) is unsuccessful after 3-6 months. In recent studies, isometric and heavy slow resistance (HSR) exercises have demonstrated potential for pain reduction and functional improvement in patellar tendinopathy.

A randomized controlled trial will be conducted at the Pakistan Sports Board (PSB) Coaching Center, Lahore. 18 Subjects will be randomized into two groups; Heavy slow resistance exercises plus eccentric exercises will be given to group A and exercises of 4 sets of 10-20 repetitions will be given. Group B will give Eccentric exercises in 3 sets of 10-20 repetitions. Pre-assessments will be taken through the Numeric Pain Rating Scale (NPRS) for pain, a goniometer for range of motion, Lower extremity function assessment scale to evaluate lower limb functional impairments, and a Visa-P scale for patellar dysfunction. Assessment will be done at baseline and post 4 weeks of training. Data will be analyzed using SPSS software version 21. The normality of data will be checked, and tests will be applied according to the normality of the data, either parametric or non-parametric tests will be used (within a group or between two groups).

The objective of the study is to compare the effects of heavy slow resistance training and eccentric overload training on pain, range of motion, and lower extremity functions in runners with patellar tendinopathy.

.

Eligibility Criteria:
Inclusion Criteria:

* anterior knee pain located on the inferior pole of the patella for at least 3 months while practicing sport;
* age between 18 and 45 years old;
* practicing any kind of sports at least 3 times a week
* score less than 80 on the Victorian Institute of Sport Assessment-Patellar questionnaire (VISA-p).

Exclusion Criteria:

* Knee surgery within the previous 6 months;
* Chronic joint diseases;
* Corticosteroid injection in the patellar tendon within the previous 3 months;
* Anti-inflammatory, analgesic, or antibiotic medications within the previous 48 hours;
* Any other concomitant treatment for PT
Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract

The purpose of this study is to determine if Chlamydial infections persist in the rectum of females who have had a sexually transmitted infection of Chlamydia.


Eligibility Criteria:
Inclusion Criteria:

* 11-19 years old
* Female
* Diagnosis of Chlamydia on enrollment visit
* Invitation to participate control group

Exclusion Criteria:

* Age out of range
* Negative Chlamydia screen (unless qualifies for control group)
* Unable to provide needed samples
Elucidate Vasodilatory Capacity From Histology-Defined Analysis of Coronary CT Angiography

Coronary CT Angiography (CCTA) may be an ideal modality to fill gaps in understanding the extent and rate of progression coronary artery disease. The investigators have developed an image analysis software ElucidVivo that estimates relevant indices, including fractional flow reserve (FFR) . In this study, the investigators aim to assess the value of ElucidVivo-based plaque morphology characterization for predicting non-invasive FFR in patients with suspected coronary artery disease (CAD) who had undergone clinically indicated coronary CTA and invasive coronary angiography (ICA) for physical FFR measurement.

Invasive FFR is a clinically validated measure of lesion-specific ischemia and is preferred over visual estimation of diameter stenosis for clinical decisions regarding coronary revascularization. FFR derived from coronary CTA (FFRct) using computational fluid dynamics (CFD)-based software has been shown to be a reasonably accurate estimate of invasive FFR and is included in contemporary guidelines as a decision-tool for management of patients with intermediate stenosis on coronary CTA. However, other methods have limitations. It is understood that the burden and type of coronary atherosclerosis, in addition to lumen stenosis, significantly impacts the vasodilatory capacity of the vessel walls which may provide a more interpretable analysis and broader clinical acceptance.

Eligibility Criteria:
Inclusion Criteria:

* Subject must have successfully completed at least one (possibly multiple) CCTA for known or suspected coronary artery disease.
* CCTA was no more than 60 days earlier (and not later)

Exclusion Criteria:

* Subject has a history of percutaneous coronary intervention (PCI) with stent implantation and/or coronary artery bypass grafting (CABG)
* Subject with insufficient CCTA image quality (defined strictly as documented in the ElucidVivo Reading Manual)
Determining Change In Blood Pressure Due to Environment and Loudness

Determine the effects of environment and sound on initial and average triplicate screening blood pressure done according to clinical practice guidelines with an automated device.

Standardly obtained blood pressures obtained in a noisy, busy, public space will be higher than attended blood pressures obtained (1) in the same environment but with earplugs to minimize sound and (2) in a quiet, private space without surrounding activity.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years

Exclusion Criteria:

* Hearing loss requiring hearing aids
* Presence of the following on both arms: rashes, gauze dressings, casts, edema, paralysis, tubes, open sores or wounds, A-V shunts.
* Being mentally impaired
* Being pregnant
* Arm circumference exceeding 55 cm.
OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)

ARMD is the main cause of visual disability after 50 years old in France. Patients with active neovascular ARMD are treated with intravitreal injections of antiVEGF. Reinjections criteria are decrease of best corrected visual acuity or active neovascularization's signs (mostly found on macular OCT but also on angiography when necessary).

The aim of this study is to evaluate the link between active neovascularization found on OCT and eye fixation quality measured with microperimetry in ARMD patients treated with antiVEGF.

Quality of eye fixation and exudative signs presents or not present on OCT will be gathered at each consultation over the two-years follow-up for each patient. The mean central retinal sensitivity, the best corrected visual acuity and the bivariate contour ellipse area will also be gathered.

In case no link will be found, for instance bad fixation quality without exudative signs on OCT or good fixation stability despite exudative signs on OCT, microperimetry should have an interest to improve reinjections criteria with a treatment more suitable to the patient.


Eligibility Criteria:
Inclusion Criteria:

* patients \> 50 years old,
* With neovascular ARMD
* who need an induction treatment (de novo patients or patients who had their last intravitreal injection of antiVEGF more than 6 months ago)

Exclusion Criteria:

* Other maculopathies
* Severe glaucoma with central visual field defect
* Diabetic patients
* Corneal, lens or vitreous opacities interfering in OCT analysis
* Attention or comprehension deficit